Nancy Krieger - 01 Feb 2022 Form 4 Insider Report for Talaris Therapeutics, Inc. (TRML)

Role
Chief Medical Officer
Signature
/s/ Mary Kay Fenton, attorney-in-fact
Issuer symbol
TRML
Transactions as of
01 Feb 2022
Net transactions value
$0
Form type
4
Filing time
02 Feb 2022, 17:02:24 UTC
Next filing
13 Sep 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TALS Stock Option (Right to Buy) Award $0 +190,000 $0.000000 190,000 01 Feb 2022 Common Stock 190,000 $9.10 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option shall vest as follows: 25% shall vest on February 1, 2023; and the remaining shall vest in 36 equal monthly installments thereafter.